Veeva Systems

Veeva Systems is an American enterprise software company dedicated to the life sciences sector. Founded in 2007 by Peter Gassner and Matt Wallach, the company developed a specialized cloud-based software model for pharmaceutical, biotechnology, medical-device, and related organizations. Its systems support commercial operations, research and development, regulatory processes, quality management, clinical operations, content governance, and other activities involved in bringing medicines and healthcare products to market. The company’s focus on life sciences differentiates it from broad horizontal enterprise-software providers. Pharmaceutical and biotechnology companies operate under extensive regulatory requirements, manage large volumes of controlled documentation and data, and coordinate work across research sites, manufacturing facilities, commercial teams, regulators, and external partners. Veeva’s products are designed around these sector-specific workflows rather than treating life sciences as one of many general-purpose industries. Veeva introduced Veeva Vault in 2011, establishing a major product platform for regulated content and process management. Vault has subsequently been associated with a range of applications covering clinical operations, regulatory information, quality, safety, and commercial content. Veeva also developed customer relationship management and commercial applications, including Veeva CRM, and data products such as Veeva Network. These offerings are intended to help life sciences companies manage interactions with healthcare professionals and organizations, maintain trusted reference data, and coordinate compliant commercial activity. Veeva became a public company through an initial public offering on the New York Stock Exchange in October 2013. Its customer base has included large multinational pharmaceutical companies and smaller biotechnology businesses, with publicly referenced customers including Bayer, Boehringer Ingelheim, Eli Lilly, Gilead Sciences, Merck & Co., Novartis, Alkermes, Alnylam Pharmaceuticals, bluebird bio, and Idorsia. The company has operated internationally while maintaining its headquarters in Pleasanton, California. In February 2021, Veeva became the first publicly traded company to convert to a public benefit corporation. That corporate form formally recognizes public-benefit considerations alongside shareholder interests and became an important part of the company’s stated governance identity. Veeva also had a longstanding partnership with Salesforce, whose platform was used in aspects of Veeva’s earlier commercial software strategy. The companies were competitors as well as partners, and Veeva ended that partnership in 2025. Veeva remains an active public enterprise-software brand whose principal identity is tied to regulated, cloud-based infrastructure for life sciences. Its business spans software, data, and consulting services, with products used to support activities across drug development, pharmaceutical manufacturing, regulatory compliance, and commercial operations.

Veeva Systems was established in 2007 by Peter Gassner and Matt Wallach to build cloud software specifically for life sciences companies. The founders’ industry focus addressed a structural problem in pharmaceutical and biotechnology operations: companies needed software capable of handling regulated content, auditability, complex approval processes, specialized data, and collaboration across research, manufacturing, regulatory, and commercial functions. Rather than positioning itself as a general-purpose software supplier, Veeva developed a vertical enterprise model centered on the operating requirements of life sciences. A significant early milestone came in 2011 with the introduction of Veeva Vault. Vault was created as a cloud content-management platform for regulated life sciences work and became the foundation for applications supporting areas such as clinical operations, regulatory information, quality management, safety, and commercial content. The platform approach enabled Veeva to extend its presence beyond a single departmental application and into connected processes involving controlled documents, submissions, approvals, and organizational records. Veeva also developed commercial software, including Veeva CRM, to support interactions between life sciences companies and healthcare professionals or organizations. Veeva Network added capabilities associated with life sciences reference data and customer or organization information. Together, these product families gave the company a broader portfolio spanning commercial execution, data management, research and development, content, and compliance-oriented operations. The company entered the public markets in October 2013 through an initial public offering on the New York Stock Exchange. Public-company status increased the visibility of Veeva as a specialist enterprise-software provider and supported its expansion among large pharmaceutical companies, biotechnology firms, and other life sciences organizations. Publicly cited customers have included Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Alkermes, Alnylam Pharmaceuticals, bluebird bio, and Idorsia. Veeva’s commercial history also reflects a complicated relationship with Salesforce. Veeva had partnered with Salesforce while developing and delivering parts of its commercial software strategy, but Salesforce was also a competitor in enterprise customer-management technology. The partnership ended in 2025, marking a further separation between the two companies and highlighting Veeva’s development as an increasingly independent industry platform. In February 2021, Veeva converted into a public benefit corporation. This was a notable governance decision because the company became the first publicly traded company reported to have adopted that form. Public benefit corporation status formally permits the company to consider specified public-benefit objectives alongside conventional shareholder interests. For Veeva, the change reinforced a corporate identity built around long-term relationships with regulated customers and the wider life sciences ecosystem. Veeva remains headquartered in Pleasanton, California, and operates internationally. Its current identity combines cloud applications, industry data, and consulting services. The company’s software is used across activities associated with drug development and pharmaceutical manufacturing, as well as the commercial and regulatory processes surrounding those activities. Its history is therefore best understood as the growth of a specialized vertical SaaS provider from a focused life sciences startup into a publicly traded enterprise platform.

1. 2025Salesforce partnership ends

   Veeva ends its partnership with Salesforce after operating in a relationship that included both collaboration and competition.

   Source
2. 2021Conversion to public benefit corporation

   Veeva converts to public benefit corporation status and is described as the first publicly traded company to do so.

   Source
3. 2013Initial public offering

   Veeva becomes publicly traded through an initial public offering on the New York Stock Exchange.

   Source
4. 2011Veeva Vault is introduced

   Veeva launches Vault, a cloud content-management system designed for regulated life sciences work.

   Source
5. 2007Veeva Systems is founded

   Peter Gassner and Matt Wallach establish Veeva Systems to provide cloud software for life sciences organizations.

   Source

A specialized cloud and data platform for regulated life sciences organizations, emphasizing industry-specific workflows, compliance, and end-to-end support across research, manufacturing, quality, regulatory, and commercial activities.

• Veeva VaultLife sciences cloud platform and applications2011

  Veeva Vault is the company’s principal cloud platform for regulated content and processes. Introduced in 2011, it supports applications used across clinical operations, regulatory information management, quality management, safety, and commercial content. Its role is to help organizations control documents and data, manage review and approval workflows, and maintain traceable processes in environments where compliance and auditability are essential.

• Veeva CRMLife sciences customer relationship management

  Veeva CRM is a customer relationship management offering built for life sciences commercial teams. It supports activities such as planning and recording interactions with healthcare professionals and organizations, coordinating field operations, and managing compliant commercial engagement. The product is designed around pharmaceutical and biotechnology requirements rather than the broader set of industries served by general-purpose CRM software.

• Veeva NetworkLife sciences data management

  Veeva Network provides life sciences organizations with capabilities for managing and using reference information about healthcare professionals, organizations, and related commercial entities. Such data can support customer engagement, territory planning, compliance processes, and coordination across commercial systems. Its positioning reflects Veeva’s broader strategy of combining applications with industry-specific data.

• 2025End the Salesforce partnershipStrategy

  Veeva and Salesforce had a relationship involving partnership and competition in enterprise customer-management software.

  What changed. Veeva ended its partnership with Salesforce.

  Aftermath. The decision further distinguished Veeva’s independent industry platform strategy from Salesforce’s broader enterprise-software approach.

  Source
• 2021Adopt public benefit corporation statusStrategy

  Veeva operated as a publicly traded specialist software company while emphasizing long-term responsibilities to customers, employees, and the life sciences ecosystem.

  What changed. The company converted to a public benefit corporation in February 2021.

  Aftermath. The conversion gave public-benefit considerations a formal place in the company’s corporate structure and was reported as a first among publicly traded companies.

  Source

• 2025Veeva ends its partnership with Salesforce

  Veeva ended its partnership with Salesforce, a relationship that had coexisted with competition between the two companies in enterprise software.

  Other
  Source
• 2021Veeva converts to a public benefit corporation

  Veeva adopted public benefit corporation status, becoming the first publicly traded company reported to have made that conversion.

  Other
  Source
• 2013Veeva Systems becomes a public company

  Veeva completed its initial public offering and began trading on the New York Stock Exchange.

  Other
  Source

1. Veeva Systems
2. Veeva Systems official website
3. Veeva leadership